PortalPublikationenMUC1, MUC2, MUC5AC, and MUC6 in colorectal cancer: expressio...

MUC1, MUC2, MUC5AC, and MUC6 in colorectal cancer: expression profiles and clinical significance

Standard

MUC1, MUC2, MUC5AC, and MUC6 in colorectal cancer: expression profiles and clinical significance. / Betge, Johannes; Schneider, Nora I; Harbaum, Lars; Pollheimer, Marion J; Lindtner, Richard A; Kornprat, Peter; Ebert, Matthias P; Langner, Cord.

in: VIRCHOWS ARCH, Jahrgang 469, Nr. 3, 09.2016, S. 255-65.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Betge, J, Schneider, NI, Harbaum, L, Pollheimer, MJ, Lindtner, RA, Kornprat, P, Ebert, MP & Langner, C 2016, 'MUC1, MUC2, MUC5AC, and MUC6 in colorectal cancer: expression profiles and clinical significance', VIRCHOWS ARCH, Jg. 469, Nr. 3, S. 255-65. https://doi.org/10.1007/s00428-016-1970-5

APA

Betge, J., Schneider, N. I., Harbaum, L., Pollheimer, M. J., Lindtner, R. A., Kornprat, P., Ebert, M. P., & Langner, C. (2016). MUC1, MUC2, MUC5AC, and MUC6 in colorectal cancer: expression profiles and clinical significance. VIRCHOWS ARCH, 469(3), 255-65. https://doi.org/10.1007/s00428-016-1970-5

Vancouver

Betge J, Schneider NI, Harbaum L, Pollheimer MJ, Lindtner RA, Kornprat P et al. MUC1, MUC2, MUC5AC, and MUC6 in colorectal cancer: expression profiles and clinical significance. VIRCHOWS ARCH. 2016 Sep;469(3):255-65. https://doi.org/10.1007/s00428-016-1970-5

Bibtex

@article{d376d029d9a947e4a2360ca51614d6c0,
title = "MUC1, MUC2, MUC5AC, and MUC6 in colorectal cancer: expression profiles and clinical significance",
abstract = "Mucin glycoprotein expression can be altered during the carcinogenic process. The impact on the prognosis of patients with colorectal cancer (CRC) is controversial. We analyzed tumors from 381 patients for MUC1, MUC2, MUC5AC, and MUC6 expression by immunohistochemical staining, using tissue microarrays. Progression-free and cancer-specific survival were determined using the Kaplan-Meier method. Expression of intestinal mucin MUC2 was lost in 85 (23 %) CRCs, and patients with MUC6-negative tumors showed shorter progression-free survival (PFS, p = 0.043). Gastric mucins MUC5AC and MUC6 showed high (>50 %) aberrant expression in 28 (8 %) and 9 (2 %) cases, respectively. High expression of MUC5AC was associated with longer PFS (p = 0.055). High expression of MUC6 was associated with 100 % PFS (p = 0.024) and longer cancer-specific survival (CSS, p = 0.043). MUC1 was expressed in 238 (64 %) tumors and had no impact on outcome. When analysis was restricted to stages II and III, loss of MUC2 was associated with adverse outcome. Overexpression of both MUC5AC and MUC6 significantly predicted favorable PFS and CSS. In conclusion, loss of MUC2 expression proved to be a predictor of adverse outcome, while the gain of aberrant expression of MUC5AC and particularly of MUC6 was associated with favorable outcome in CRC, notably in intermediate stages II and III.",
keywords = "Journal Article",
author = "Johannes Betge and Schneider, {Nora I} and Lars Harbaum and Pollheimer, {Marion J} and Lindtner, {Richard A} and Peter Kornprat and Ebert, {Matthias P} and Cord Langner",
year = "2016",
month = sep,
doi = "10.1007/s00428-016-1970-5",
language = "English",
volume = "469",
pages = "255--65",
journal = "VIRCHOWS ARCH",
issn = "0945-6317",
publisher = "Springer",
number = "3",

}

RIS

TY - JOUR

T1 - MUC1, MUC2, MUC5AC, and MUC6 in colorectal cancer: expression profiles and clinical significance

AU - Betge, Johannes

AU - Schneider, Nora I

AU - Harbaum, Lars

AU - Pollheimer, Marion J

AU - Lindtner, Richard A

AU - Kornprat, Peter

AU - Ebert, Matthias P

AU - Langner, Cord

PY - 2016/9

Y1 - 2016/9

N2 - Mucin glycoprotein expression can be altered during the carcinogenic process. The impact on the prognosis of patients with colorectal cancer (CRC) is controversial. We analyzed tumors from 381 patients for MUC1, MUC2, MUC5AC, and MUC6 expression by immunohistochemical staining, using tissue microarrays. Progression-free and cancer-specific survival were determined using the Kaplan-Meier method. Expression of intestinal mucin MUC2 was lost in 85 (23 %) CRCs, and patients with MUC6-negative tumors showed shorter progression-free survival (PFS, p = 0.043). Gastric mucins MUC5AC and MUC6 showed high (>50 %) aberrant expression in 28 (8 %) and 9 (2 %) cases, respectively. High expression of MUC5AC was associated with longer PFS (p = 0.055). High expression of MUC6 was associated with 100 % PFS (p = 0.024) and longer cancer-specific survival (CSS, p = 0.043). MUC1 was expressed in 238 (64 %) tumors and had no impact on outcome. When analysis was restricted to stages II and III, loss of MUC2 was associated with adverse outcome. Overexpression of both MUC5AC and MUC6 significantly predicted favorable PFS and CSS. In conclusion, loss of MUC2 expression proved to be a predictor of adverse outcome, while the gain of aberrant expression of MUC5AC and particularly of MUC6 was associated with favorable outcome in CRC, notably in intermediate stages II and III.

AB - Mucin glycoprotein expression can be altered during the carcinogenic process. The impact on the prognosis of patients with colorectal cancer (CRC) is controversial. We analyzed tumors from 381 patients for MUC1, MUC2, MUC5AC, and MUC6 expression by immunohistochemical staining, using tissue microarrays. Progression-free and cancer-specific survival were determined using the Kaplan-Meier method. Expression of intestinal mucin MUC2 was lost in 85 (23 %) CRCs, and patients with MUC6-negative tumors showed shorter progression-free survival (PFS, p = 0.043). Gastric mucins MUC5AC and MUC6 showed high (>50 %) aberrant expression in 28 (8 %) and 9 (2 %) cases, respectively. High expression of MUC5AC was associated with longer PFS (p = 0.055). High expression of MUC6 was associated with 100 % PFS (p = 0.024) and longer cancer-specific survival (CSS, p = 0.043). MUC1 was expressed in 238 (64 %) tumors and had no impact on outcome. When analysis was restricted to stages II and III, loss of MUC2 was associated with adverse outcome. Overexpression of both MUC5AC and MUC6 significantly predicted favorable PFS and CSS. In conclusion, loss of MUC2 expression proved to be a predictor of adverse outcome, while the gain of aberrant expression of MUC5AC and particularly of MUC6 was associated with favorable outcome in CRC, notably in intermediate stages II and III.

KW - Journal Article

U2 - 10.1007/s00428-016-1970-5

DO - 10.1007/s00428-016-1970-5

M3 - SCORING: Journal article

C2 - 27298226

VL - 469

SP - 255

EP - 265

JO - VIRCHOWS ARCH

JF - VIRCHOWS ARCH

SN - 0945-6317

IS - 3

ER -